News

"The preclinical data we presented at ASH in December 2015 supported the evaluation of M281 as a strategy for the rapid and reversible suppression of pathogenic autoantibodies or

The Committees recommended the inclusion of abuse-deterrent labeling for intranasal (11 to 4) and intravenous (9 to 6) routes of abuse. They voted against inclusion of abuse-deterrent labeling

Each unit consists of (i) one share of Pieris’ common stock or non-voting series A convertible preferred stock convertible into one share of common stock, (ii) 0.40 warrants

Over three years, Adimab will use its proprietary, yeast-based discovery platform to generate IgGs or bispecifics for development as therapeutic products for multiple targets chosen by Innovent. Innovent

Endoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer patients to prevent recurrence as well as new breast cancer. Dr. Steve Quay, President

The collaboration will help support multiple Phase 1 and 2 clinical trials testing Opdivo as monotherapy, in combination with Yervoy, or in regimens with other agents, radiation or

The double-blind, placebo-controlled study randomized 153 patients into four treatment arms. All participants were on statin therapy and had LDL-C levels between 70 and 190 mg/dL. At baseline,

The 395-patient study assessed the safety and efficacy of 5 mg and 10 mg of tofacitinib administered twice daily in adult patients with active psoriatic arthritis (PsA) who

Under the terms of the agreement, Innovent will gain access to EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop multiple bispecific antibodies for the Chinese market, including the